Transgene 11月9日更新个体化癌症疫苗进展：TG4050头颈癌随访逾3年无病生存率保持100%，肺癌疫苗TG4070已启动1期试验
法国斯特拉斯堡消息—Transgene（巴黎泛欧交易所：TNG）2026年11月9日公布其个体化新抗原治疗性疫苗平台 myvac 的业务进展与截至2026年9月30日的财务状况更新，重点为两款候选疫苗 TG4050 与 TG4070。
公司称，TG4050 随机1/2期试验（NCT04183166）的强劲1期数据已发表于《自然·通讯》，显示该疫苗在术后及放化疗后复发风险高的早期头颈鳞状细胞癌患者中显示临床原理验证：安全性良好，并诱导出持久的新抗原特异性 T 细胞应答，随访超过3年后无病生存率（DFS）保持100%。该研究的2期部分正在进行，公司预计今年年底前获得首批免疫学数据，目标在2027年一场科学会议上展示，并预计在2028年第一季度末前公布 TG4050 2期试验的顶线结果。
在肺癌方面，公司已启动一项随机1期试验，评估 TG4070 联合纳武利尤单抗，用于新辅助纳武利尤单抗加化疗后接受切除的非小细胞肺癌患者，试验编号 EUCT 2025-520946-31-00。Transgene 在公告中介绍，公司开发基于 myvac 平台的个体化新抗原治疗性疫苗以预防癌症复发，并拥有一系列基于病毒载体的候选产品。
Transgene Updates Its Individualized Cancer Vaccine Program on November 9: TG4050 Maintains 100% Disease-Free Survival After More Than Three Years in Head and Neck Cancer, and the TG4070 Lung Cancer Trial Has Started
STRASBOURG, France — Transgene (Euronext Paris: TNG) provided a business update on November 9, 2026, on its myvac-based individualized neoantigen therapeutic vaccine assets TG4050 and TG4070, together with its financial position as of September 30, 2026.
The company said strong Phase 1 data from the randomized Phase 1/2 trial of TG4050 (NCT04183166), demonstrating clinical proof of principle in patients with early-stage head and neck squamous cell carcinoma at high risk of relapse following surgery and (chemo)-radiotherapy, have been published in Nature Communications. TG4050 showed a favourable safety profile and induced persistent neoantigen-specific T cell responses, with a 100% disease-free survival rate sustained after more than three years of follow-up. The Phase 2 part of the study is ongoing; the company expects first immunological data by year end, aims to present them at a scientific conference in 2027, and expects to communicate topline results from the Phase 2 trial by the end of the first quarter of 2028.
For lung cancer, the company has initiated a randomized Phase 1 trial evaluating TG4070 in combination with nivolumab in patients with resected non-small cell lung cancer following neoadjuvant nivolumab plus chemotherapy (EUCT 2025-520946-31-00). In the release, Transgene described itself as a biotechnology company developing its myvac individualized neoantigen therapeutic vaccine platform to prevent cancer recurrence, alongside a portfolio of viral vector-based candidates.
https://www.morningstar.com/news/globe-newswire/1001302669/transgene-reports-continued-clinical-progress-and-q3-2026-financial-update （Transgene 2026年11月9日临床进展与第三季财务更新公告）
科学
—-
发布：GSM·美国（发布链接）
图片来源：Wikipedia/Wikimedia Commons 词条主图：Transgene
GSM Global · 本篇英文版 English edition of this story
